Therefore, it is reasonable to infer that specific antagonists or antibodies targeting CXCL12/CXCR4 axis alone or combined with chemotherapy should be effective and worthy of further studies as a potential treatment strategy in advanced GC, just like in other malignancies. This evidence concerns the gene CXCL12 and gastric cancer.